Financial Snapshot

Revenue
$247.2M
TTM
Gross Margin
66.82%
TTM
Net Earnings
-$25.46M
TTM
Current Assets
Q4 2024
Current Liabilities
Q4 2024
Current Ratio
393.68%
Q4 2024
Total Assets
Q4 2024
Total Liabilities
Q4 2024
Book Value
$378.4M
Q4 2024
Cash
Q4 2024
P/E
-54.60
Nov 29, 2024 EST
Free Cash Flow
$11.20M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2006 2005 2004 2003
Revenue $333.8M $280.3M $321.8M $296.4M $192.2M $127.1M $76.57M $500.0K $40.63M $28.14M $27.31M $22.10M $20.45M $2.900M $300.0K $0.00 $0.00
YoY Change 19.07% -12.89% 8.57% 54.22% 51.25% 65.95% 15213.8% -98.77% 44.37% 3.07% 23.57% 8.05% 866.67%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2006 2005 2004 2003
Revenue $333.8M $280.3M $321.8M $296.4M $192.2M $127.1M $76.57M $500.0K $40.63M $28.14M $27.31M $22.10M $20.45M $2.900M $300.0K $0.00 $0.00
Cost Of Revenue $102.0M $112.2M $97.39M $63.10M $45.46M $32.99M $21.37M $10.88M $10.27M $8.541M $9.078M $7.930M $2.800M $1.700M $0.00 $0.00
Gross Profit $178.3M $209.6M $199.0M $129.1M $81.61M $43.58M $26.95M $29.75M $17.87M $18.77M $13.02M $12.52M $200.0K -$1.300M $0.00 $0.00
Gross Profit Margin 63.61% 65.13% 67.14% 67.17% 64.23% 56.92% 5390.6% 73.22% 63.5% 68.72% 58.92% 61.22% 6.9% -433.33%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2006 2005 2004 2003
Selling, General & Admin $205.5M $201.2M $196.4M $152.2M $102.7M $75.43M $44.65M $32.90M $31.89M $20.60M $14.91M $10.70M $10.11M $8.100M $6.100M $3.500M $1.700M
YoY Change 2.14% 2.43% 29.05% 48.26% 36.1% 68.96% 35.7% 3.17% 54.84% 38.15% 39.31% 5.84% 32.79% 74.29% 105.88% 466.67%
% of Gross Profit 112.83% 93.72% 76.48% 79.52% 92.43% 102.44% 122.07% 107.2% 115.25% 79.45% 82.19% 80.75% 4050.0%
Research & Development $72.41M $81.87M $90.39M $76.53M $48.94M $30.71M $14.51M $12.39M $12.39M $9.333M $3.846M $3.176M $4.752M $12.30M $8.800M $9.500M $5.800M
YoY Change -11.56% -9.43% 18.12% 56.36% 59.36% 111.6% 17.16% 0.02% 32.7% 142.67% 21.1% -33.16% 39.77% -7.37% 63.79% 123.08%
% of Gross Profit 45.91% 43.13% 38.45% 37.91% 37.63% 33.3% 45.96% 41.63% 52.22% 20.5% 24.39% 37.95% 6150.0%
Depreciation & Amortization $14.19M $14.39M $5.200M $2.700M $1.900M $1.600M $1.200M $1.200M $2.920M $796.0K $512.0K $663.0K $1.072M $910.0K $820.0K $620.0K
YoY Change -1.33% 176.65% 92.59% 42.11% 18.75% 33.33% 0.0% -58.9% 266.83% 55.47% -22.78% -38.15% 10.98% 32.26%
% of Gross Profit 8.07% 2.48% 1.36% 1.47% 1.96% 2.75% 4.45% 9.82% 4.45% 2.73% 5.09% 8.56% 455.0%
Operating Expenses $293.0M $483.7M $399.0M $326.1M $214.7M $151.6M $92.15M $47.25M $77.96M $40.08M $26.06M $22.96M $22.79M $20.30M $14.90M $13.00M $7.500M
YoY Change -39.42% 21.22% 22.35% 51.88% 41.64% 64.52% 95.03% -39.4% 94.54% 53.81% 13.51% 0.71% 36.24% 14.62% 73.33% 158.62%
Operating Profit $40.77M -$203.4M -$77.23M -$29.73M -$22.53M -$24.53M -$15.58M -$20.29M -$37.33M -$11.93M $1.250M -$857.0K -$2.342M -$20.10M -$16.20M -$13.00M -$7.500M
YoY Change -120.05% 163.32% 159.81% 31.95% -8.17% 57.48% -23.24% -45.64% 212.87% -1054.56% -245.86% -63.41% 24.07% 24.62% 73.33% 158.62%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2006 2005 2004 2003
Interest Expense $11.77M $11.87M $3.762M $160.0K $271.0K $985.0K -$3.701M -$5.863M -$1.860M -$1.587M -$2.100M -$2.100M -$2.700M $400.0K $100.0K $0.00 $0.00
YoY Change -0.86% 215.44% 2251.25% -40.96% -72.49% -126.61% -36.88% 215.22% 17.2% -24.43% 0.0% -22.22% 300.0%
% of Operating Profit 28.86% -168.0%
Other Income/Expense, Net $12.09M $13.22M $997.0K -$2.362M $2.778M $585.0K -$32.64M -$36.98M -$1.920M -$188.0K -$78.00K -$536.0K -$14.00K -$100.0K -$200.0K $0.00 $0.00
YoY Change -8.52% 1225.98% -142.21% -185.03% 374.87% -101.79% -11.73% 1825.78% 921.28% 141.03% -85.45% 3728.57% -50.0% -100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2006 2005 2004 2003
Pretax Income $52.86M -$190.1M -$76.23M -$32.09M -$19.75M -$23.95M -$48.22M -$57.27M -$41.36M -$13.71M -$719.0K -$3.542M -$5.059M -$19.90M -$16.40M -$13.00M -$7.500M
YoY Change -127.8% 149.42% 137.58% 62.47% -17.53% -50.33% -15.81% 38.46% 201.76% 1806.4% -79.7% -29.99% 21.34% 26.15% 73.33% 108.33%
Income Tax $310.0K $141.0K $379.0K -$1.426M -$1.036M -$1.979M -$1.434M -$1.709M -$1.606M $0.00 -$1.500M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income 0.59%
Net Earnings $52.55M -$190.3M -$76.61M -$30.66M -$18.71M -$21.97M -$46.76M -$55.47M -$39.47M -$13.71M $781.0K -$3.542M -$5.059M -$19.90M -$16.60M -$13.00M -$7.500M
YoY Change -127.62% 148.37% 149.86% 63.85% -14.81% -53.02% -15.71% 40.54% 187.95% -1855.06% -122.05% -29.99% 19.88% 27.69% 73.33% 108.33%
Net Earnings / Revenue 15.74% -67.88% -23.81% -10.34% -9.74% -17.29% -61.06% -11093.8% -97.14% -48.7% 2.86% -16.03% -24.74% -686.21% -5533.33%
Basic Earnings Per Share $1.00 -$3.54 -$1.44 -$0.59 -$0.40 -$0.52 -$1.31 -$2.38 -$2.39 -$1.16 $0.13 -$3.50 -$5.01
Diluted Earnings Per Share $0.93 -$3.54 -$1.44 -$0.59 -$0.40 -$0.52 -$1.31 -$2.38 -$2.39 -$1.16 $0.10 -$3.50 -$5.01 -$715.8K -$597.1K -$467.6K -$269.8K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2006 2005 2004 2003
Cash & Short-Term Investments $235.4M $293.1M $348.5M $224.7M $38.20M $64.60M $16.90M $17.30M $29.90M $36.40M $5.100M $5.800M $15.90M $24.80M
YoY Change -19.68% -15.9% 55.09% 488.22% -40.87% 282.25% -2.31% -42.14% -17.86% 613.73% -12.07% -35.89%
Cash & Equivalents $82.20M $89.92M $348.5M $134.7M $38.20M $64.60M $16.90M $17.30M $29.90M $36.40M $5.100M $5.800M $7.900M $24.80M
Short-Term Investments $153.2M $203.2M $0.00 $90.00M $8.000M $0.00
Other Short-Term Assets $7.763M $9.216M $7.928M $3.800M $3.600M $1.800M $1.400M $1.200M $1.300M $500.0K $300.0K $200.0K $300.0K $200.0K
YoY Change -15.77% 16.25% 108.63% 5.56% 100.0% 28.57% 16.67% -7.69% 160.0% 66.67% 50.0% 50.0%
Inventory $19.47M $19.23M $17.19M $10.00M $6.000M $4.900M $5.500M $5.500M $800.0K $700.0K $500.0K $600.0K $300.0K $400.0K
Prepaid Expenses
Receivables $51.06M $66.31M $59.76M $34.60M $24.10M $9.800M $3.000M $2.800M $2.400M $2.700M $2.300M $1.000M $400.0K $0.00
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $313.7M $387.8M $433.4M $273.1M $71.90M $81.10M $26.80M $26.70M $34.40M $40.30M $8.200M $7.600M $17.00M $25.50M
YoY Change -19.11% -10.5% 58.68% 279.83% -11.34% 202.61% 0.37% -22.38% -14.64% 391.46% 7.89% -33.33%
Property, Plant & Equipment $65.14M $70.22M $40.04M $25.90M $9.200M $4.100M $2.100M $2.900M $2.400M $2.000M $1.600M $2.100M $5.600M $1.100M
YoY Change -7.24% 75.38% 54.58% 181.52% 124.39% 95.24% -27.59% 20.83% 20.0% 25.0% -23.81% 409.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.939M $4.350M $6.046M $1.300M $1.300M $200.0K $9.600M $200.0K $200.0K $200.0K $100.0K $200.0K $500.0K $300.0K
YoY Change -55.43% -28.05% 365.08% 0.0% 550.0% -97.92% 4700.0% 0.0% 0.0% 100.0% -50.0% 66.67%
Total Long-Term Assets $153.1M $155.1M $133.3M $95.40M $79.80M $49.60M $56.80M $50.00M $21.20M $20.80M $1.700M $2.300M $6.100M $1.400M
YoY Change -1.31% 16.42% 39.69% 19.55% 60.89% -12.68% 13.6% 135.85% 1.92% 1123.53% -26.09% 335.71%
Total Assets $466.8M $543.0M $566.6M $368.5M $151.7M $130.7M $83.60M $76.70M $55.60M $61.10M $9.900M $9.900M $23.10M $26.90M
YoY Change
Accounts Payable $12.87M $9.942M $13.34M $9.700M $5.500M $4.700M $3.400M $3.100M $1.600M $1.100M $600.0K $600.0K $2.000M $700.0K
YoY Change 29.47% -25.46% 37.49% 76.36% 17.02% 38.24% 9.68% 93.75% 45.45% 83.33% 0.0% 185.71%
Accrued Expenses $35.43M $40.60M $43.79M $25.60M $18.80M $11.20M $8.700M $9.400M $5.500M $2.500M $1.800M $2.900M $1.700M $1.200M
YoY Change -12.73% -7.29% 71.06% 36.17% 67.86% 28.74% -7.45% 70.91% 120.0% 38.89% -37.93% 41.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $200.0K $15.70M $22.80M $2.900M $6.000M $4.500M $1.500M $4.000M $200.0K
YoY Change -98.73% -31.14% 686.21% -51.67% 33.33% 200.0% 1900.0%
Total Short-Term Liabilities $78.07M $75.98M $77.30M $69.20M $34.80M $19.50M $42.90M $40.80M $10.20M $11.10M $7.600M $6.400M $7.900M $2.400M
YoY Change 2.76% -1.72% 11.71% 98.85% 78.46% -54.55% 5.15% 300.0% -8.11% 46.05% 18.75% 229.17%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $18.30M $1.100M $12.90M $5.500M $11.40M $13.40M $6.200M $100.0K
YoY Change -100.0% 1563.64% -91.47% 134.55% -51.75% -14.93% 6100.0%
Other Long-Term Liabilities $127.3M $36.11M $23.03M $20.30M $15.90M $12.30M $23.30M $9.000M $3.100M $3.300M $6.300M $2.000M $6.000M $2.100M
YoY Change 252.56% 56.78% 13.44% 27.67% 29.27% -47.21% 158.89% 190.32% -6.06% -47.62% 215.0% 185.71%
Total Long-Term Liabilities $127.3M $36.11M $23.03M $20.30M $15.90M $12.30M $41.60M $10.10M $16.00M $8.800M $17.70M $15.40M $12.20M $2.200M
YoY Change 252.56% 56.78% 13.44% 27.67% 29.27% -70.43% 311.88% -36.88% 81.82% -50.28% 14.94% 454.55%
Total Liabilities $205.5M $112.1M $100.7M $90.80M $52.70M $34.80M $89.70M $57.20M $26.10M $19.80M $25.30M $21.90M $20.20M $4.600M
YoY Change 83.35% 11.25% 10.95% 72.3% 51.44% -61.2% 56.82% 119.16% 31.82% -21.74% 15.53% 339.13%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $1.3902 Billion

About CareDx, Inc.

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 635 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The firm offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. The company develops and provides diagnostic surveillance testing services for various transplant recipients.

Industry: Services-Medical Laboratories Peers: Cogent Biosciences, Inc. Design Therapeutics, Inc. Editas Medicine, Inc. Erasca, Inc. Forma Therapeutics Holdings, Inc. GERON CORP Keros Therapeutics, Inc. Kura Oncology, Inc. POINT Biopharma Global Inc.